FDA Approves Mesenchymal Stromal Cell Therapy for GVHD
The U.S. Food and Drug Administration (FDA) has approved remestemcel-L (Ryoncil, Mesoblast Ltd), a pioneering mesenchymal stromal cell (MSC) therapy for treating steroid-refractory acute graft-versus-host disease (SR-aGVHD) in children aged 2 months and older. This approval makes Ryoncil the first mesenchymal stromal cell therapy for GVHD to receive FDA authorization, marking a major milestone in […]